CRMD logo

CORMEDIX INC

CRMDNASDAQ
🏆 #2702 by market capUS Equity
——
Quote unavailable
🔔
Track CRMD
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$639M
Small Cap
📈Revenue Growth (YoY)
280.5%
High Growth
📊Gross Margin
82.8%
High
💵FCF Margin
54.2%
Strong
⚖️P/S Ratio
1.3x
Cheap
Otter Score
—
Insufficient data
No chart data available for CRMD.

Trading Snapshot

Day Range
—
52-Week Range
$6.13 – $13.02
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
77.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$312M
Last Q Revenue
$102M
P/E Ratio
3.3
P/S Ratio
1.3x
EPS (TTM)
$2.10
Dividend Yield
—
Dilution (1yr)
+52.7%
CRMD logo

CORMEDIX INC

CRMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$312M▲ +617.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.5%▼ −4.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$150M▼ −771.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$173M▼ −440.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
93.9M▲ +52.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$3M▼ −$43M YoY
StockOtter · stockotter.space

About CORMEDIX INC

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.